Cardioprotective mechanism of omega-3 polyunsaturated fatty acids

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid and docosahexaenoic acid, are widely regarded as cardioprotective. Several large-scale, randomized clinical trials have shown that dietary intake of omega-3 PUFAs improves the prognosis of patients with symptomatic heart failure or recent myocardial infarction. Therefore, dietary consumption of omega-3 PUFA is recommended in international guidelines for the general population to prevent the occurrence of cardiovascular diseases (CVDs). However, the precise mechanisms underlying the cardioprotective effects of omega-3 PUFAs are not fully understood. Omega-3 PUFAs can be incorporated into the phospholipid bilayer of cell membranes and can affect membrane fluidity, lipid microdomain formation, and signaling across membranes. Omega-3 PUFAs also modulate the function of membrane ion channels, such as Na and L-type Ca channels, to prevent lethal arrhythmias. Moreover, omega-3 PUFAs also prevent the conversion of arachidonic acid into pro-inflammatory eicosanoids by serving as an alternative substrate for cyclooxygenase or lipoxygenase, resulting in the production of less potent products. In addition, a number of enzymatically oxygenated metabolites derived from omega-3 PUFAs were recently identified as anti-inflammatory mediators. These omega-3 metabolites may contribute to the beneficial effects against CVDs that are attributed to omega-3 PUFAs.

Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalJournal of Cardiology
Volume67
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Omega-3 Fatty Acids
Unsaturated Fatty Acids
Ion Channels
Cardiovascular Diseases
Membrane Fluidity
Eicosapentaenoic Acid
Lipoxygenase
Eicosanoids
Docosahexaenoic Acids
Prostaglandin-Endoperoxide Synthases
Membrane Lipids
Arachidonic Acid
Cardiac Arrhythmias
Phospholipids
Anti-Inflammatory Agents
Randomized Controlled Trials
Heart Failure
Myocardial Infarction
Cell Membrane
Guidelines

Keywords

  • 18-Hydroxyeicosapentaenoic acid
  • Anti-inflammation
  • Cardiovascular disease
  • Omega-3 polyunsaturated fatty acids
  • Specialized proresolving mediators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. / Endo, Jin; Arita, Makoto.

In: Journal of Cardiology, Vol. 67, No. 1, 01.01.2016, p. 22-27.

Research output: Contribution to journalArticle

@article{e8be3ba270eb45eaacf24dc1eb8b232c,
title = "Cardioprotective mechanism of omega-3 polyunsaturated fatty acids",
abstract = "Omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid and docosahexaenoic acid, are widely regarded as cardioprotective. Several large-scale, randomized clinical trials have shown that dietary intake of omega-3 PUFAs improves the prognosis of patients with symptomatic heart failure or recent myocardial infarction. Therefore, dietary consumption of omega-3 PUFA is recommended in international guidelines for the general population to prevent the occurrence of cardiovascular diseases (CVDs). However, the precise mechanisms underlying the cardioprotective effects of omega-3 PUFAs are not fully understood. Omega-3 PUFAs can be incorporated into the phospholipid bilayer of cell membranes and can affect membrane fluidity, lipid microdomain formation, and signaling across membranes. Omega-3 PUFAs also modulate the function of membrane ion channels, such as Na and L-type Ca channels, to prevent lethal arrhythmias. Moreover, omega-3 PUFAs also prevent the conversion of arachidonic acid into pro-inflammatory eicosanoids by serving as an alternative substrate for cyclooxygenase or lipoxygenase, resulting in the production of less potent products. In addition, a number of enzymatically oxygenated metabolites derived from omega-3 PUFAs were recently identified as anti-inflammatory mediators. These omega-3 metabolites may contribute to the beneficial effects against CVDs that are attributed to omega-3 PUFAs.",
keywords = "18-Hydroxyeicosapentaenoic acid, Anti-inflammation, Cardiovascular disease, Omega-3 polyunsaturated fatty acids, Specialized proresolving mediators",
author = "Jin Endo and Makoto Arita",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.jjcc.2015.08.002",
language = "English",
volume = "67",
pages = "22--27",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "1",

}

TY - JOUR

T1 - Cardioprotective mechanism of omega-3 polyunsaturated fatty acids

AU - Endo, Jin

AU - Arita, Makoto

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid and docosahexaenoic acid, are widely regarded as cardioprotective. Several large-scale, randomized clinical trials have shown that dietary intake of omega-3 PUFAs improves the prognosis of patients with symptomatic heart failure or recent myocardial infarction. Therefore, dietary consumption of omega-3 PUFA is recommended in international guidelines for the general population to prevent the occurrence of cardiovascular diseases (CVDs). However, the precise mechanisms underlying the cardioprotective effects of omega-3 PUFAs are not fully understood. Omega-3 PUFAs can be incorporated into the phospholipid bilayer of cell membranes and can affect membrane fluidity, lipid microdomain formation, and signaling across membranes. Omega-3 PUFAs also modulate the function of membrane ion channels, such as Na and L-type Ca channels, to prevent lethal arrhythmias. Moreover, omega-3 PUFAs also prevent the conversion of arachidonic acid into pro-inflammatory eicosanoids by serving as an alternative substrate for cyclooxygenase or lipoxygenase, resulting in the production of less potent products. In addition, a number of enzymatically oxygenated metabolites derived from omega-3 PUFAs were recently identified as anti-inflammatory mediators. These omega-3 metabolites may contribute to the beneficial effects against CVDs that are attributed to omega-3 PUFAs.

AB - Omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid and docosahexaenoic acid, are widely regarded as cardioprotective. Several large-scale, randomized clinical trials have shown that dietary intake of omega-3 PUFAs improves the prognosis of patients with symptomatic heart failure or recent myocardial infarction. Therefore, dietary consumption of omega-3 PUFA is recommended in international guidelines for the general population to prevent the occurrence of cardiovascular diseases (CVDs). However, the precise mechanisms underlying the cardioprotective effects of omega-3 PUFAs are not fully understood. Omega-3 PUFAs can be incorporated into the phospholipid bilayer of cell membranes and can affect membrane fluidity, lipid microdomain formation, and signaling across membranes. Omega-3 PUFAs also modulate the function of membrane ion channels, such as Na and L-type Ca channels, to prevent lethal arrhythmias. Moreover, omega-3 PUFAs also prevent the conversion of arachidonic acid into pro-inflammatory eicosanoids by serving as an alternative substrate for cyclooxygenase or lipoxygenase, resulting in the production of less potent products. In addition, a number of enzymatically oxygenated metabolites derived from omega-3 PUFAs were recently identified as anti-inflammatory mediators. These omega-3 metabolites may contribute to the beneficial effects against CVDs that are attributed to omega-3 PUFAs.

KW - 18-Hydroxyeicosapentaenoic acid

KW - Anti-inflammation

KW - Cardiovascular disease

KW - Omega-3 polyunsaturated fatty acids

KW - Specialized proresolving mediators

UR - http://www.scopus.com/inward/record.url?scp=84955187127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955187127&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2015.08.002

DO - 10.1016/j.jjcc.2015.08.002

M3 - Article

VL - 67

SP - 22

EP - 27

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

IS - 1

ER -